Skip to main content

Table 5 Baseline clinical characteristics of patients in different β2-MG groups in validation cohort A

From: New risk score for predicting steroid resistance in patients with focal segmental glomerulosclerosis or minimal change disease

Ln(β2-MG/uCr)Low tertile (≤ 2.45)High tertile (> 2.45)
VariableN = 56N = 55OR (95% CI)
No response (%)5 (8.9)29 (52.7)11.38 (3.94–32.84)#
Age (year)33.0 ± 14.238.0 ± 15.91.02 (0.997–1.05)
Gender (%) male33 (58.9)32 (58.2)1.03 (0.49–2.20)
MAP (mmHg)92.1 ± 10.894.3 ± 18.91.01 (0.99–1.04)
BMI (kg/m2)23.7 ± 3.824.9 ± 3.91.08 (0.97–1.21)
Ln(Pro) (g/24 h)1.8 ± 0.41.8 ± 0.41.06 (0.45–2.46)
Albumin (g/L)16.5 ± 5.216.4 ± 7.00.996 (0.94–1.06)
eGFR (mL/min/1.73 m2)100.9 ± 23.586.0 ± 39.00.99 (0.97–0.998)*
TG (mmol/L)2.9 ± 2.44.4 ± 4.21.20 (1.002–1.44)*
TC (mmol/L)10.0 ± 3.711.1 ± 4.91.06 (0.97–1.17)
Interstitial fibrosis (%)25 (44.6)39 (70.9)3.02 (1.387–6.63)#
Inflammatory cell infiltration (%)21 (37.5)33 (60.0)2.50 (1.16–5.37)*
Tubular atrophy (%)24 (42.9)33 (60.0)2.00 (0.94–4.26)
  1. MAP: mean arterial pressure; BMI: body mass index; Ln(Pro): natural logarithm of urine protein; eGFR: estimated glomerular filtration rate; TG: triglyceride; TC: total cholesterol; MAU: microalbumin; ORM: orosomucoid; RBP: retinol binding protein; β2-MG: β2-microglobulin; α1-MG: α1-microglobulin
  2. *P < 0.05, #P < 0.01